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ABSTRACT:  The breast cancer susceptibility gene
BRCA2 was isolated in 1995.  BRCA2 is a large gene
comprising 10,254 nucleotides and 26 coding exons.
Neither the nucleotide nor the predicted protein
sequences (comprising 3,418 amino acids) have
provided substantial clues about its function.  As a
result, researchers have been trying to elucidate the
function using a combination of cell biological and
biochemical methods and the construction of animal
models using gene targeting in mice.  Recent data
suggest that BRCA2 may participate in pathways
associated with recombination or double-strand DNA
break repair and may act by either sensing or
responding to DNA damage.  In addition, there is
evidence to suggest that BRCA2 functions in a
manner similar to the previously isolated breast cancer
susceptibility gene BRCA1.
INTRODUCTION
Germline mutations of BRCA2 confer a high
lifetime risk of female breast cancer and are
associated with an increased risk of male breast
cancer, ovarian cancer, prostate cancer and
pancreatic cancer [1–7].  The gene is thought to
behave as a tumour suppressor; tumours from
families linked to BRCA2 show consistent loss of
the wild-type allele.  In addition, loss of
heterozygosity studies indicate that the BRCA2
locus (on chromosome 13q12–13) is frequently
deleted in sporadic breast and ovarian cancers [8–
10].  However, few somatic BRCA2 mutations
have been found in these tumours [10–14].
The nucleotide sequence and predicted
BRCA2 protein shows very little homology to
previously isolated genes; no domains have been
identified which provide obvious clues to the
function of the protein [2,3].  One potentially
important functional domain located in a central
portion of the gene is an amino acid motif which
is repeated eight times (termed the BRC repeats)
[15].  The majority of these repeats are well
conserved between human, mouse, monkey, pig,
dog and hamster even though the overall
conservation of BRCA2 is poor [16].  Yeast two-
hybrid screens have recently shown that six out
of eight BRC repeats specifically bind to the
RAD51 protein which has been implicated in
recombination or double-strand DNA break
repair [17].  At the amino terminus, another
region of the BRCA2 gene which is highly
conserved between human and mouse is
homologous to the activation domain of c-Jun, a
known transcription factor [18].  This region,
which includes exon 3, has been shown to
activate transcription in vitro.  The transcriptional
activation ability is significantly reduced when a
naturally occurring missense mutation is
introduced into the sequence.
The BRCA2 gene is widely transcribed at
relatively low levels [2,3].  Two studies show
that BRCA2 mRNA expression is cell cycle
dependent and is induced at the G1/S boundary
[19,20].  Expression appears to be greatest in
rapidly proliferating cells and is down regulated
in response to growth factor deprivation.  In
addition, BRCA2 is coordinately expressed with
BRCA1 in mammary epithelial cells suggesting
that these genes may be induced by, and function
in, overlapping regulatory pathways.  There is
also evidence to suggest that BRCA2
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each other.  Antibodies recognising different
epitopes of the BRCA2 protein have been used to
study its cell-cycle regulation as well as its
cellular localisation.  Cell fractionation followed
by western blotting indicates that BRCA2 is
predominantly nuclear [21].  Western blot
analyses also suggest that BRCA2 expression
levels vary during the cell cycle; BRCA2
expression is induced in MCF7 cells in late
G1/early S-phase following release from serum
starvation [21].
The murine homologue of BRCA2 has been
cloned.  Mouse BRCA2 is poorly conserved; it
shows an overall 59% identity and 72% similarity
with human BRCA2 [22,23].  This is similar to
the mouse:human homology observed for the
BRCA1 gene but is significantly less than across
species conservation of other tumour suppressor
genes.  Analysis of the expression pattern of
mouse BRCA2 reveals that it is widely
transcribed, like human BRCA2.  Quantitative
reverse transcription PCR and northern analysis
suggest that expression is greatest in the thymus,
testis and ovary [22,23].  In addition, BRCA2
appears to be highly expressed in rapidly
proliferating cells in the developing mouse
embryo, similar to the expression pattern of
BRCA1 [23].
THE PHENOTYPES OF BRCA2
INACTIVATION IN THE MOUSE
Analysis of the phenotypic consequences of
mutations in whole organisms may provide
useful clues to the function of specific genes.
The phenotype in mice which have been
engineered to be heterozygous for mutations
analogous to those identified in humans
sometimes closely resembles the phenotype
observed in humans (e.g. inactivation of the APC
gene in the colorectal cancer susceptibility
syndrome familial adenomatous polyposis [24]).
In other instances the phenotype is considerably
different between mouse and humans (e.g.
inactivation of the WT1 gene in Wilms tumour
[25]).  Despite the different phenotypes observed
between mice and humans in some syndromes, it
remains likely that the interactions between
specific gene products and the biochemical
pathways in which they are involved will be
conserved across species.
To date, five independent mouse strains have
been engineered in which the BRCA2 gene has
been targeted and completely or partly knocked
out by homologous recombination [26–30].  The
locations of the mutations are different but each
is predicted to produce a truncated BRCA2
protein, although this has not been formally
demonstrated due to the lack of antibodies
specific to BRCA2.  In all cases, mice which are
heterozygous for the BRCA2 mutant allele
(BRCA2+/−) have so far failed to show any sign
of susceptibility to mammary tumours or indeed
any other phenotype.  In three of these mouse
strains, intercrosses of BRCA2+/− animals
produced only wild type and heterozygous
progeny suggesting that homozygous mutant
progeny (BRCA2−/−) were not viable [26–28].
Analysis of the development of these mice during
embryogenesis shows that BRCA2−/− embryos
fail at a very early stage, after approximately 6.5
to 7.5 days of gestation.  The remaining two mice
strains, however, have a different phenotype.  In
both strains, some homozygotes survived birth.
Surviving BRCA2−/− mice were growth retarded
compared with BRCA2+/− and BRCA2+/+
littermates and were infertile [29,30].  In
addition, the majority of neonates and adult mice
had a distinctively kinked tail suggestive of
developmental defects in skeletal structures.  In
both of these strains, BRCA2 null mice died at a
relatively early age (between 11 and 22 weeks)
concomitant with the development of metastatic
thymic lymphomas.
GENOTYPE–PHENOTYPE
CORRELATION IN BRCA2 NULL
MICE
Why do mice homozygous for different
BRCA2 mutations have differing phenotypes?
One possible explanation is that the penetrance of
the BRCA2 mutation differs depending on the
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evidence to suggest that this may partly be true in
the two strains of BRCA2−/− mice which are
viable; in both cases the proportion of
homozygotes which survive varies depending on
background, suggesting that other genetic factors
are modifying penetrance.  However, modifying
effects of different genetic backgrounds are
unlikely to account for all of the phenotypic
variation observed amongst these mouse strains.
Another possible explanation for this
phenotypic variation is that different mutations
have different functional effects, possibly
through the loss or retention of functionally
important domains in the different predicted
truncated proteins.  The most significant regions
of functional homology identified in BRCA2 to
date are the BRC repeats most of which
specifically bind RAD51 in vitro [15–17].  Three
of the five BRCA2 mutations which have been
used to generate BRCA2−/− mice are predicted
to truncate the BRCA2 protein before the first of
these BRC repeats [26–28]; these strains of mice
all have an embryonic lethal phenotype.  In the
two strains in which some BRCA2−/− mice
survive, the truncated protein is predicted to
retain three and seven of the eight repeats
respectively [29–30].  These data suggest that the
BRC repeats are functionally significant and that
their loss or retention directly affects the
phenotype of BRCA2−/− mice.
It is intriguing that the region which contains
the BRC repeats is also associated with
phenotypic variation in humans [6].  Germline
truncating mutations in this region (termed the
ovarian cancer cluster region, OCCR, and
encompassing nucleotides 3035 to 6629) are
associated with an increased risk of ovarian
cancer and/or a decreased risk of breast cancer
compared with mutations elsewhere in the gene
[6].  These data provide further support for a
significant functional role of the BRC repeats and
their association with RAD51.  Figure 1
highlights the similarities between mouse and
human BRCA2, summarises current knowledge
Fig. 1.  Comparison between human and mouse BRCA2 genes. The genomic structure of human BRCA2 is known
[3]; vertical lines along the length of the gene represent the approximate location of coding exons. The genomic
structure of mouse BRCA2 is unknown [16–18,26].  Black bars represent regions of putative functional significance
[16–18,26]. Hatched bars represent regions of high identity between mouse and human genes.  Shaded bars
represent regions of RAD51 specific binding.  The location of truncating mutations in mice are illustrated with
respect to the phenotypes of BRCA2−/− mice.  A region of phenotypic variation in humans, the ovarian cancer
cluster region [6] is also illustrated.S.A. Gayther and B.A.J. Ponder / Clues to the Function of the Tumour Susceptibility Gene BRCA2 4
Fig. 2.  Hypothetical explanation for the putative interaction between BRCA2, BRCA1 and RAD51, and their
postulated role in repairing DNA damage (adapted from [39]).  Mutations in these genes (represented by "rough"
ovals) lead to the accumulation of unrepaired DNA damage.  p53, p21 and other cell cycle checkpoint genes are
upregulated in response to this damage leading to cell cycle arrest.  However, when these genes also become the
victim of unrepaired DNA damage cells lose the ability to initiate cell cycle arrest leading to unregulated growth and
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with respect to regions of the gene which appear
to be functionally significant and correlates the
phenotypic variation observed in mice and
humans with genotype.
REDUCED CELLULAR
PROLIFERATION IN BRCA2−/− MICE
Mice which are nullizygous for BRCA1
exhibit growth retardation and embryonic
lethality similar to that of three strains of
BRCA2−/− mice [27,31,33].  Growth arrest in
BRCA1−/− mice was shown to be caused by a
decrease in the rate of cellular proliferation rather
than an increase in the rate of apoptosis [31].  In
BRCA2−/− mice the rate of cellular proliferation
has been investigated at various stages of
embryogenesis by measuring the incorporation of
5-bromo-2'-deoxyuridine (BRDU) into DNA in
the S phase of the cell cycle and by direct
measurement of the rates of proliferation of
mouse embryonic fibroblasts (MEF) [26,29,30].
Homozygous mutant embryos do not exhibit any
significant proliferative differences from
heterozygous or wild-type embryos up to 6.5
days.  However, at E7.5 the proliferation ability
of BRCA2−/− embryos is severely impaired [28].
Likewise, homozygous mutant MEFs initially
divide at rates similar to heterozygous and wild
type MEFs before undergoing a striking
proliferative impairment with successive
passages [29,30].
The phenotype of BRCA2 mutant mice
changes when they are crossed with p53 mutant
mice to create BRCA2/p53 nullizygotes [27].
Although the embryonic lethal phenotype is
maintained, BRCA2/p53 null embryos are
partially rescued to the extent that embryonic
lethality occurs 1–2 days later in gestation.  This
may indicate that the early lethality observed in
the BRCA2 mutant mice is dependent on the
function of p53; cell cycle checkpoint activation
and cessation of embryonic development may
result from the activation of p53 in response to
loss of BRCA2.  In cells null for p53 as well as
for BRCA2 the same constraints on
hyperproliferation may no longer exist and as a
result BRCA2−/− embryos are able to survive
longer.  In support of this, p53 expression is
increased in BRCA2 homozygous mutant MEFs
and is accompanied by an increase in the
expression of p21, a G1 cell cycle inhibitor which
is upregulated by p53 as part of the growth arrest
response to DNA damage [27–30].
BRCA2 AND RESPONSE TO DNA
DAMAGE
The embryonic lethal phenotype which is
observed in BRCA2−/− mice resembles the
phenotype observed in mice null for BRCA1 and
RAD51 [27,31–33].  p53 and p21 are also
upregulated in response to the growth arrest
which occurs in BRCA1 null mice [27,31].
RAD51 is the homologue of a bacterial
recombination protein recA and has been
implicated in the repair of double-strand DNA
breaks [34,35].  RAD51 associates with BRCA1
and BRCA2 in vitro (although a direct interaction
has only been shown for BRCA2) and co-
localises with BRCA1 on meiotic chromosomes
[17,36].  This implies a role for BRCA1 and
BRCA2 in sensing and/or responding to DNA
damage.  The response of BRCA2−/− blastocysts
and MEFs to DNA damaging agents provides
support for this [26,29,37].  Blastocysts null for
BRCA2 were shown to be significantly more
senstive to γ -irradiation than wild-type or
heterozygous embryos [26].  In another study,
BRCA2−/− MEFs were defective in repairing
DNA damage induced by exposure to X-
irradiation in single cell electrophoresis
("comet") assays [29].  Finally, BRCA2−/−
MEFs are significantly more sensitive to UV-
light and the monofunctional alkylating agent
MMS (methyl-methane sulphonate) than BRCA2
heterozygous and wild-type MEFs [37].  The
phenotype of BRCA2−/− MEFs resembles that of
mouse cells deficient in excision repair protein
ECCR1: in addition to sensitivity to UV light and
MMS, ECCR1 deficient cells suffer proliferative
impairment with successive passaging and are
frequently polyploid [38].  BRCA2−/− cells also
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exhibit excessive structural abnormalities with
successive passaging [37].  This may imply a role
for BRCA2 in DNA excision repair.
How do mutations of BRCA2 cause cancer,
and more specifically breast and ovarian cancer?
It has been hypothesised that BRCA2 may
form a complex of proteins which includes
BRCA1 and RAD51 (Figure 2) [39].  In this
model, cells in which BRCA1 or BRCA2 have
been inactivated are unable to repair DNA
damage.  In response, p53 and p21 are
upregulated leading to checkpoint activation and
cell cycle arrest.  However, in the absence of
functional BRCA1 or BRCA2 protein, DNA
damage which affects p53, p21 and other genes
involved in cell cycle regulation would also
remain unrepaired.  Thus, the brakes on cellular
proliferation would be released resulting
ultimately in tumour formation.
In summary, evidence is accumulating to
suggest that BRCA2 belongs to a class of
proteins, which includes the mismatch repair
proteins associated with predisposition to
colorectal cancer, which behave as 'caretakers' of
genome integrity.  Furthermore, BRCA2 appears
to have many characteristics in common with the
previously isolated breast cancer predisposition
gene BRCA1, suggesting that these two proteins
may be coregulated in overlapping pathways.
Considering the universal role which is predicted
for BRCA2 and BRCA1, it is unclear why
mutations in these genes should specifically
predispose individuals to breast and ovarian
cancer.  Future research is likely to clarify the
role of BRCA2 as a protein which either senses
or responds to DNA damage, and its putative
interaction with RAD51 and BRCA1.
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